BISBENZOXAZOLE DERIVATIVES HAD ANTI-PROLIFERATIVE EFFECT ON HUMAN CANCER CELLS
Abstract
ABSTRACT
A series of symmetric bis-benzoxazole derivatives were synthesized using one-pot cyclisation reaction between 4-fluoro substituted 2-aminophenol and suitable carboxylic acids. Synthesized compounds’ anticancer activities were tested by using MTT assay on human prostate (DU145) and breast (MCF7) cancer cells. Screening results revealed that all compounds possessed a high level anti-cancer potential by significantly decreasing the cell proliferation in prostate and breast cancer cell lines. Our compounds exerted their anti-proliferative effects in a dose and time dependent manner. Our results suggest that they can be highly potent since they were biologically active even at low concentration ranges. Our study presents a series of new bis-benzoxazole based compounds with potential therapeutic effects against tumor cells. Therefore, characterization of new generation bis-benzoxazole derivatives will have a significant contribution on the development of new era anti-cancer drug candidates.
Keywords
Bisbenzoxazole,Breast cancer,Prostate cancer,Anti-proliferative,Anti-cancer
References
- [1] Williams GH, Stoeber K. Cell cycle markers in clinical oncology. CurrOpin Cell Biol 2007; 19: 1- 6.
- [2] Bower JJ et al. Topoisomerase IIalpha maintains genomic stability through decatenationG(2) checkpoint signaling. Oncogene 2010; 29: 4787–4799.
- [3] Hartwell LH, Kastan MB. Cell cycle control and cancer. Science1994; 266: 1821–1828.
- [4] Marie Classon EH. The retinoblastoma tumor suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910–917.
- [5] Xu B, Kim ST, Kastan MB. Involvement of Brca1 in S-Phase and G2-Phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21: 3445–3450.
- [6] Rui-Hong Wang HY, Chu-Xia Deng. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci 2004; 101: 17108–17113.
- [7] Santarpia L, et al. DNA repair gene patters as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 2013; 18: 1063–1073.
- [8] Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001; 98: 10869–10874.
- [9] Nakagawa T, et al. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines. Cancer Res 2004; 64: 4826–4832.
- [10] Hinck L, Näthke I. Changes in cell and tissue organization in cancer of the breast and colon. Curr Opin Cell Biol 2014;0:87–95.